The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology
By The Cancer News Team
This article summarizes the transcript from Session 11 of the 5th Binaytara Precision Oncology Summit
Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology
By The Cancer News Team
This article summarizes the transcript from Session 11 of the 5th Binaytara Precision Oncology Summit
Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology
By The Cancer News Team
This article summarizes the transcript from Session 11 of the 5th Binaytara Precision Oncology Summit
$40 Test Could Save Lives: Researcher Cracks Code on Aggressive Leukemia Affecting One-Third of Asian Patients
By The Cancer News Team
Dr. Dikshat Gupta’s $40 diagnostic test for Ph-like ALL offers a groundbreaking, affordable solution to detect aggressive leukemia subtypes common in Asian populations, advancing equitable cancer care.
$40 Test Could Save Lives: Researcher Cracks Code on Aggressive Leukemia Affecting One-Third of Asian Patients
By The Cancer News Team
Dr. Dikshat Gupta’s $40 diagnostic test for Ph-like ALL offers a groundbreaking, affordable solution to detect aggressive leukemia subtypes common in Asian populations, advancing equitable cancer care.
$40 Test Could Save Lives: Researcher Cracks Code on Aggressive Leukemia Affecting One-Third of Asian Patients
By The Cancer News Team
Dr. Dikshat Gupta’s $40 diagnostic test for Ph-like ALL offers a groundbreaking, affordable solution to detect aggressive leukemia subtypes common in Asian populations, advancing equitable cancer care.
More Treats, Fewer Tricks: Taming the Terror of Metastatic Cancer
By Dr. Binay Shah
Dr. Binay Shah explains the science of metastatic cancer, the “seed and soil” hypothesis, and how new therapies are transforming this once-terminal disease into one filled with hope.
More Treats, Fewer Tricks: Taming the Terror of Metastatic Cancer
By Dr. Binay Shah
Dr. Binay Shah explains the science of metastatic cancer, the “seed and soil” hypothesis, and how new therapies are transforming this once-terminal disease into one filled with hope.
More Treats, Fewer Tricks: Taming the Terror of Metastatic Cancer
By Dr. Binay Shah
Dr. Binay Shah explains the science of metastatic cancer, the “seed and soil” hypothesis, and how new therapies are transforming this once-terminal disease into one filled with hope.
The Hidden Role of Physical Therapy in Breast Cancer Survivorship
By The Cancer News Team
Dr. Becky Miller, PT, explains how oncology physical therapy empowers breast cancer survivors to regain strength, manage lymphedema, and rebuild confidence after treatment.
The Hidden Role of Physical Therapy in Breast Cancer Survivorship
By The Cancer News Team
Dr. Becky Miller, PT, explains how oncology physical therapy empowers breast cancer survivors to regain strength, manage lymphedema, and rebuild confidence after treatment.
The Hidden Role of Physical Therapy in Breast Cancer Survivorship
By The Cancer News Team
Dr. Becky Miller, PT, explains how oncology physical therapy empowers breast cancer survivors to regain strength, manage lymphedema, and rebuild confidence after treatment.
National Breast Cancer Awareness Month
By Dr. Chandra Lalita Kakarala
Dr. Chandra Lalita Kakarala explores the global burden, prevention, and education surrounding breast cancer in honor of National Breast Cancer Awareness Month 2025.
National Breast Cancer Awareness Month
By Dr. Chandra Lalita Kakarala
Dr. Chandra Lalita Kakarala explores the global burden, prevention, and education surrounding breast cancer in honor of National Breast Cancer Awareness Month 2025.
National Breast Cancer Awareness Month
By Dr. Chandra Lalita Kakarala
Dr. Chandra Lalita Kakarala explores the global burden, prevention, and education surrounding breast cancer in honor of National Breast Cancer Awareness Month 2025.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
Breast Cancer 101
By Dr. Fengting Yan
Learn about breast cancer symptoms, prevention, treatment options, and disparities worldwide in this expert-reviewed overview by Dr. Fengting Yan of the Swedish Cancer Institute.
Breast Cancer 101
By Dr. Fengting Yan
Learn about breast cancer symptoms, prevention, treatment options, and disparities worldwide in this expert-reviewed overview by Dr. Fengting Yan of the Swedish Cancer Institute.
Breast Cancer 101
By Dr. Fengting Yan
Learn about breast cancer symptoms, prevention, treatment options, and disparities worldwide in this expert-reviewed overview by Dr. Fengting Yan of the Swedish Cancer Institute.
How One PhD Student Is Bridging Cervical Cancer Research and Community Impact
By The Cancer News Team
How one PhD student is bridging cervical cancer research and community outreach to improve prevention and treatment access in underserved regions of Nepal.
How One PhD Student Is Bridging Cervical Cancer Research and Community Impact
By The Cancer News Team
How one PhD student is bridging cervical cancer research and community outreach to improve prevention and treatment access in underserved regions of Nepal.
How One PhD Student Is Bridging Cervical Cancer Research and Community Impact
By The Cancer News Team
How one PhD student is bridging cervical cancer research and community outreach to improve prevention and treatment access in underserved regions of Nepal.